Results 191 to 200 of about 35,674 (297)

"They should be like penicillin": barriers to the integration of medications for opioid use disorder in specialty treatment programs. [PDF]

Addict Sci Clin Pract
Desai IK, Burke K, Raikes J, Xu J, Li Y, Saloner B, Feder KA, Krawczyk N.   +7 more
europepmc   +1 more source

Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

Addiction, EarlyView.
Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi   +9 more
wiley   +1 more source

Holding the line: Provider and patient perspectives on Medications for Opioid Use Disorder continuity during the war in Ukraine. [PDF]

PLoS One
Pykalo I, Filippovych M, Zeziulin O, Dvoriak S, Dayton L, Latkin C.   +5 more
europepmc   +1 more source

Medication Treatment for Opioid Use Disorders:

Delaware Journal of Public Health, 2017
openaire   +2 more sources

Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference‐in‐differences time series

Addiction, EarlyView.
Abstract Background and aims Evidence regarding the impacts of supervised drug consumption services (SDC) remains mixed, and few evaluations have used individual‐level, linkable health data to examine service withdrawal. In September 2024, the Red Deer overdose prevention site (OPS) in Alberta, Canada, was scheduled for closure, with operations ceasing
Nathaniel Day, Kym Kaufmann, Daniel John Alexander Devoe, Vanja Grubac, Alessia DiMarzo, Haisa Osmanli, Vanessa Norton, Shelly Vik, Nickie Mathew, Robert Lawrence Tanguay, Anees Bahji   +10 more
wiley   +1 more source

Regional perspectives: Substance use related problems in Ethiopia

Addiction, EarlyView.
Abstract Ethiopia, with a population exceeding 130 million, presents a complex landscape for understanding substance use disorders. The country's diverse cultural heritage, varying regional practices, and evolving socioeconomic conditions create unique factors of substance use that differ markedly from global trends.
Tesfa M. Yimer, Wubalem Fekadu, Janni Leung, Awoke Mihretu, Solomon Teferra   +4 more
wiley   +1 more source

Structural and Policy Determinants of Access to Medications for Opioid Use Disorder Among Pregnant People in U.S. Jails. [PDF]

Int J Environ Res Public Health
Lakshman M, Murali S, Kramer CT, Sufrin CB, Fix RL.   +4 more
europepmc   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source

Circulating plasma protein biomarkers associated with risk of negative clinical outcomes in virally suppressed people with HIV receiving medications for opioid use disorder. [PDF]

Front Mol Biosci
Azzoni L, Zhang L, Zhu K, Fair M, Hiserodt E, Mounzer K, Wallin JJ, Montaner LJ, Cai Y.   +8 more
europepmc   +1 more source

What anabolic–androgenic steroids reveal about the limits of current harm reduction models

Addiction, EarlyView.
Abstract Background Harm reduction has largely been shaped by responses to psychoactive drug use where the most urgent harms are acute. These models focus on overdose, blood‐borne viruses, and rapid‐onset toxicity related harms. When applied wholesale to anabolic–androgenic steroids (AAS), they obscure the distinctive pharmacology, consumer typologies,
Timothy Piatkowski, Jason M. Nagata, Suzanne Nielsen   +2 more
wiley   +1 more source